Domagrozumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Domagrozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetGDF-8
Clinical data
SynonymsPF-06252616
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6366H9826N1690O2008S46
Molar mass143.6 kDa g·mol−1

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]

This drug was developed by Pfizer.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Domagrozumab&oldid=867662929"